KRTX News and Press, Karuna Therapeutics Inc. From 10/31/22

Summary Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of man...

Clinical-stage biopharmaceutical companies Karuna Therapeutics (NASDAQ: KRTX) and Reata Pharmaceuticals (NASDAQ: RETA) are up more than 64% and 17% so far this year thanks to potential blockbuster drugs. Karuna's lead candidate, KarXT, has excited investors becau...

Summary During the third quarter of 2022, the Miller Opportunity Equity strategy generated a total return of -4.62% net of fees. Using a three-factor performance attribution model, allocation, and selection effects contributed to the strategy’s outperformance which was part...

PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its dr...

Summary Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach. Biotechs benefit if a...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophreni...

Karuna Therapeutics ( NASDAQ: KRTX ), a biotech focused on psychiatric and neurological conditions, dropped ~8% intraday Wednesday after a regulatory disclosure indicated that its Chief Financial Officer Troy Ignelzi sold more than $3 worth of company stock. According to...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before jumping directly into momentum stocks worth buying now, it’s important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock ...

Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...

Summary Karuna Therapeutics could disrupt the Schizophrenia market with its differentiated drug candidate KarXT. The drug has unique properties and has demonstrated outstanding efficacy in Phase 2 and 3 trials. Provided Karuna obtains some additional safety data demanded by th...